

ORIGINAL ARTICLE

Serum 25-Hydroxyvitamin D associated with indicators of body fat and insulin resistance in prepubertal Chilean children

G Cediel¹, C Corvalán¹, C Aguirre¹, DL de Romaña^{1,2} and R Uauy^{1,3}

BACKGROUND: Consistent data on the relation between vitamin D, body fat and insulin resistance (IR) in children are lacking. **OBJECTIVES:** (1) To evaluate the association between serum 25-Hydroxyvitamin D [25(OH)D] and key indicators of: adiposity (total and central), IR, and (2) to estimate serum 25(OH)D cut-offs that best reflect IR and total and central adiposity in children. **SUBJECTS/METHODS:** Prepubertal children ($n = 435$, ~53% girls; ~age 7 years) from the Growth and Obesity Chilean Cohort Study were evaluated for potential associations between serum 25(OH)D and indicators of: (1) total adiposity (body mass index by age (BAZ), body fat (including three-component model)), central adiposity (waist circumference and trunk fatness); (2) IR (homeostasis model assessment of IR) and insulin sensitive (quantitative insulin sensitivity check index) using standardized multiple regression models with standardized coefficients and receiver operating characteristic curves. **RESULTS:** Overall, mean serum 25(OH)D was 32.1 ± 9.2 ng ml⁻¹, while 19.4% of children were obese (BAZ ≥ 2 s.d.). Serum 25(OH)D was inversely associated with indicators of total and central adiposity and with IR indicators. Effect sizes were moderate in girls (~0.3 for adiposity and IR indicators), while, weaker values were found in boys. Serum 25(OH)D estimated cut-offs that best predicted total, central adiposity and IR were ~30 ng ml⁻¹. Children with suboptimal serum 25(OH)D (< 30 ng ml⁻¹) had a higher risk (two to three times) of being obese (high BAZ, body fat percent and/or central adiposity); and three to four times greater risk for IR. **CONCLUSIONS:** Serum 25(OH)D was inversely associated with adiposity (total and central) and IR indicators in prepubertal Chilean children. The conventional cut-off of vitamin D sufficiency (≥ 30 ng ml⁻¹) was adequate to assess obesity and IR risk in this age group.

International Journal of Obesity (2016) 40, 147–152; doi:10.1038/ijo.2015.148

INTRODUCTION

Vitamin D (VD) stimulates intestinal calcium absorption and is important to maintain adequate phosphate levels for bone mineralization, bone growth and remodeling.¹ However in the past decade, VD receptor and VD-metabolizing enzymes have been described in other tissues (for example, adipose, muscle and pancreas),^{2–4} suggesting regulatory roles beyond bone health.^{5,6}

In adults, suboptimal VD has been related with higher mortality from cardiovascular and metabolic disorders among several other diseases;⁷ the association of VD deficiency with increased adiposity and insulin resistance (IR) has been suggested as the common underlying factor for these conditions.^{8–10} In children, the evidence for an extraskeletal role for VD is scarce, particularly in developing countries. However, an inverse relationship between VD and adiposity has been shown in some studies;^{11–20} while others, show no association.^{21–23} These inconsistencies may be partly due to the use of indirect indicators of adiposity (for example, body mass index (BMI), skinfolds).²⁴ Observational studies in children suggest an inverse association between VD and IR; however, this association varies with age.^{14–16,21–23,25–32} Serum 25-Hydroxyvitamin D [25(OH)D] is accepted as a biomarker of VD status since it is the dominant and more stable form of VD. It reflects the combined effect of intake, skin synthesis, storage, blood transport protein and catabolism.³³ Serum 25(OH)D cut-offs serve to define VD status; however, since these cut-offs are based on information related to calcium metabolism and risk of rickets,³⁴

it has been questioned if they are also potentially valid to assess extraskeletal VD status.^{35,36}

Thus, the aims of the present study were: (1) to evaluate the association between serum 25(OH)D and multiple indicators of total and central adiposity and IR; and (2) to define the range of serum 25(OH)D that are more strongly associated to whole body and central adiposity and IR in a sample of >400 prepubertal Chilean children participating in a longitudinal follow-up study that includes periodic monitoring of body adiposity and associated metabolic markers.

METHODS

Subjects

The study sample was composed of 435 prepubertal children of both sexes (mean age was ~6 years for girls and 8 years for boys) participants of the Growth and Obesity Chilean Cohort Study (GOCS) conducted in Santiago, Chile (latitude 33° 27' S). Growth and Obesity Chilean Cohort Study is a study of low-middle income Chilean children born in 2002–2003 ($n = 1196$, ~50% girls) at 37 and 42 weeks gestational age with birth weight ≥ 2500 g. Growth and Obesity Chilean Cohort Study assessments include repeated anthropometric, growth and maturation assessments; as well as biological specimen collection at defined time points. Details on recruitment procedures and study design have been previously published.³⁷

Study design

For the present study we identified all Children recruited to the primary study with a negative family history of genetic metabolic disease

¹Institute of Nutrition and Food Technology, University of Chile, Santiago, Chile; ²Nutrition Research Institute, Lima, Peru and ³Department of Nutrition and Public Health Intervention Research, Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK. Correspondence: Dr C Corvalán, Institute of Nutrition and Food Technology, University of Chile, 56-2-9781436, Av El Libano 5524, INTA, Macul, Santiago, Chile.
E-mail: ccorvalan@inta.uchile.cl

Received 8 May 2015; revised 15 July 2015; accepted 20 July 2015; accepted article preview online 12 August 2015; advance online publication, 8 September 2015

(for example, type 1 diabetes), not receiving VD supplements in past 6 months and had a serum sample drawn during last visit before initiation of puberty ($n=1050$). For the present study, we included a random sample of 435 children (~53% girls). Sample size was estimated to assess magnitude of associations previously reported assuming 80% power, a two-tail significance $P < 0.05$ considering a small effect size.³⁸ Children included in the study did not differ in age (7.1 ± 0.04 ; 7.05 ± 0.06), z-score BMI for age (BAZ) (0.91 ± 0.04 ; 0.91 ± 0.05), z-score height to age (0.21 ± 0.03 ; 0.21 ± 0.04) or waist circumference (WC) (60.5 ± 0.4 ; 60.4 ± 0.3) relative to children not included (all P -value > 0.05). The Institutional Review Board of the Institute of Nutrition and Food Technology of the University of Chile approved the study. Informed consent was obtained from all parents or guardians of the children.

Vitamin D

A single nurse obtained all blood samples early in the morning (before 1000 h). Concentrations of serum 25(OH)D were measured in serum using the Liaison 25(OH)D total (D2 & D3, DiaSorin Inc, Stillwater, MN, USA), which had an inter-assay and intra-assay coefficient variation of 14.2% and 6.1%, respectively.

Adiposity

Anthropometric measures. At the time of the VD sample collection, a registered dietician measured the weight, height, WC and skinfold thickness of children using standardized procedures. Weight was measured using a portable electronic scale (Seca 770; Seca, Hamburg, Germany) with 0.1 kg precision. Height was measured with a portable stadiometer (Harpender 603; Holtain Ltd, Crosswell, UK) to the nearest 0.1 cm. WC (minimum circumference between the iliac crest and the rib cage) was measured with a metal inextensible tape (model W606PM; Luffkin, Baltimore, MD, USA) to the closest 0.1 cm. In addition, the indicator WC divide by height (WC/H) was calculated. Skinfold thickness was measured in triplicate with a Lange caliper to the nearest 0.5 mm; the mean value was used in the analysis. For all measurements the intraobserver technical measurement and the mean average bias of the observer were within the limits suggested by the World Health Organization.³⁹

Bioelectrical impedance measurements (BIA). BIA was measured using a Tanita BC-418 MA, eight-electrodes, hand-to-foot system (Tanita Corporation, Tokyo, Japan). BIA measurements were obtained in the morning, with limited physical exertion and with empty bladders and at measurement frequency of 50 kHz. Height, sex and age were entered manually, while weight was recorded automatically (accuracy within 0.1 kg).

BOD POD and deuterium dilution measurements. In a convenience subsample of 283 children (36% girls) body volume was measured by air displacement plethysmography (BOD POD, Life Measurement Instruments, Concord, CA, USA) and total body water (TBW) was determined by D2O dilution (98.9 atom % excess; Europa Scientific, Crewe, UK). This allowed us to estimate body fat (BF) using a reference method for body composition, the three-component model (3C model). Children in this subsample were slightly older than those of the total sample (8.4 ± 0.06 vs 7.1 ± 0.04 , respectively; $P < 0.05$), but had similar BAZ (1.09 ± 0.09 vs 0.91 ± 0.04 , $P > 0.05$) and WC (60.5 ± 0.4 vs 61.1 ± 0.4 , $P > 0.05$).

Indicators of total adiposity. total adiposity was defined as: (1) BMI: weight (kg)/height (m)², expressed as BMI for age z-score (BAZ), World Health Organization 2007 growth reference.⁴⁰ (2) Skinfolds: BF percentage (FM (%)) = $(1.825 * \text{BAZ}) + (0.7825 * \text{Triceps Skinfold}) + (0.3072 * \text{Biceps Skinfold}) + 15.558.3$, BIA: BF estimated based on the equipment's equation and (3) the three-component model (3C model): FM (kg) = $((2.220 * \text{BV}) - (0.764 * \text{TBW})) - (1.465 * \text{BW})$,⁴¹ where BV is body volume in liters, TBW in liters and BW, body weight in kilograms. Obesity was defined as BAZ ≥ 2 s.d. and overweight as BAZ $\geq 1 \leq 2$ s.d. High BF % was defined as ≥ 75 th percentile of the sample distribution for skinfolds, BIA, and the 3C-Model.

Indicators of central adiposity. High central adiposity was defined as: (1) WC NHANES III > 75 th percentile of Hispanic population specific by age and sex (girls at 6 years: 60.4 cm; and boys at 8 years: 66.2 cm);⁴² (2) WC/H as ≥ 0.5 cm; and (3) truncal adiposity (abdominal, suprailiac, and subscapular skinfold thicknesses)⁴³ ≥ 75 th percentile of the sample distribution.

Insulin resistance (IR)

Serum glucose concentrations. were measured with an enzymatic colorimetric technique (HUMAN; Gesellschaft für Biochemica und Diagnostica, Weisbaden, Germany); and serum insulin concentrations were assessed with a radioimmunoassay kit (Linco Research Inc, St Charles, MO). The analyses were conducted at the Nutritional Laboratory of Catholic University of Chile. This laboratory conducts daily assessments of the accuracy of the measurements by using UNITY quality control software (Bio-Rad Laboratories Inc, Hercules, CA, USA).

Insulin resistance indicators. We calculated the homeostasis model assessment of IR (HOMA-IR) as fasting glucose (mg dl⁻¹) x fasting insulin (mU ml⁻¹)/405 and quantitative insulin sensitivity check index as $1/(\log \text{ fasting insulin (mU ml}^{-1}) + \log \text{ fasting glucose (mg dl}^{-1}))$. Hyperinsulinemia was defined as ≥ 10 IU ml⁻¹ (ref. 44) and high IR was defined, according to the proposal by Keskin et al.,⁴⁵ as ≥ 3.2 ; however, given the low prevalence of IR in this sample (1.7% in girls and 6.9% in boys), we used fasting insulin and HOMA-IR ≥ 75 th percentile of the sample. Low quantitative insulin sensitivity check index was defined as ≤ 25 th percentile of the sample distribution.

Other variables

Seasonality. season of VD assessment was classified as summer (December 21 to March 20); fall (March 21 to June 20); Winter, (June 21 to September 20); and spring (September 21 to December 20).⁴⁶

Tanner staging. two health professionals (one per each sex) specially trained by a pediatric endocrinologist classified Tanner staging of the children by physical exam (palpation in girls and orchidometer in boys).^{47,48}

Statistical analyses

Data are presented as means and s.d. (s.d. = z-score). Variables with non-normal distributions were log transformed. Differences by sex were evaluated using student's *t*-test for continuous variables or χ^2 /fisher test for dichotomous variables. Linear regression models using standardized coefficients (X- mean/s.d. of the sample) were used to compare associations between serum 25(OH)D and the different adiposity e IR indicators (beta coefficient; and 95% confidence interval (CI)); adjusted for age, seasonality, and adiposity (only IR model). Interactions by sex were all significant ($P < 0.05$); thus, results are presented by sex. To determine optimal cut-offs to assess the association between serum 25(OH)D and high adiposity and IR we used receiver operating characteristic curves to estimate area under the curve (AUC), sensitivity, specificity and the maximum youden index (sensitivity- (1-specificity)), and the point with shortest distance from the point (0, 1) $((1 - \text{sensitivity})^2 + (1 - \text{specificity})^2)$.⁴⁹ These cut-offs were then used to define optimal VD and assess the associations between suboptimal VD and high adiposity and IR using logistic regression models adjusted for age, seasonality, and adiposity (IR model). Statistical analyses were conducted using Stata 11.0 (StataCorp LP, Lakeway, TX, USA).

RESULTS

General characteristics by sex are presented in Table 1. A total of 435 prepubertal children (~53% girls) with an average age of ~6 years in girls and ~8 years in boys were enrolled in the study. Mean serum 25(OH)D was slightly above 30 ng ml⁻¹ with concentrations being marginally lower among boys (31.2 in boys vs 32.9 ng ml⁻¹ in girls, $P = 0.06$). Almost a third of the girls presented concentration of 25(OH)D < 30 ng ml⁻¹ (26.3% 30-20 and 5.6% below 20 ng ml⁻¹), while 50% of the boys were below the standard VD cut-offs (39.9% 30-20 and 10.3% below 20 ng ml⁻¹). Children evaluated during fall and winter had lower 25(OH)D concentrations (31.0 ± 8.6 ng ml⁻¹, $n = 381$), than children evaluated during spring or summer (34.6 ± 11.4 ng ml⁻¹, $n = 54$) (P for seasonality differences < 0.05).

Excess weight (BAZ > 1) was prevalent in this sample, particularly among boys (~55% in boys and ~35% in girls, P -value < 0.05). Mean BF% (by skinfolds) was ~30% in both sexes; with slightly lower value when assessed by BIA. Central obesity (WC > 75 Pc) was also high compared with the US reference ~43% in both sexes, $P > 0.05$. High insulin or high HOMA-IR was

Table 1. General characteristics of 435 prepubertal Chilean children, by sex

Characteristics	Girls n = 232 X, s.d.	Boys n = 203 X, s.d.	P-value ^a
Age (years)	6.3, 0.6	8.0, 1.3	< 0.001
VD			
25-Hydroxyvitamin D [25(OH)D] (ng ml ⁻¹)	32.9, 8.2	31.2, 10.1	0.06
Insufficiency VD (≥20, < 30 ng ml ⁻¹) (%), (n)	26.3 (61)	39.9 (81)	< 0.001
Deficiency VD (< 20 ng ml ⁻¹) (%), (n)	5.6 (13)	10.3 (21)	0.07
Total Adiposity			
Weight (kg)	24.5, 4.2	32.1, 7.5	< 0.001
Height (cm)	120.4, 5.2	131.3, 8.4	< 0.001
BMI: kg m ⁻²	16.8, 2.0	18.4, 2.8	< 0.001
Height for age s.d. ^b	0.14, 0.9	0.29, 0.9	0.08
BMI for age s.d. ^b	0.65, 0.9	1.14, 1.2	< 0.001
BAZ (≥1, < 2 s.d.) (%), (n) ^c	24.9 (58)	30.5 (62)	< 0.001
BAZ (≥ 2 s.d.) (%), (n) ^c	9.9 (23)	24.1 (49)	< 0.001
Body fat % skinfolds GOCS ^c	26.5, 4.5	29.9, 7.7	< 0.001
Body fat % bioimpedance (BIA) ^d	24.1, 3.7	24.0, 5.2	0.85
Body fat % 3C model ^e	27.9, 7.9	30.9, 6.9	< 0.001
Central Adiposity			
WC (cm) ^f	57.7, 5.8	63.8, 8.1	< 0.001
WC ≥75th percentile NHANES (%), (n) ^f	43.1 (100)	43.3 (88)	0.96
WC/Height (cm) ^f	0.48, 0.04	0.48, 0.05	0.12
WC/height > 0.5 (%), (n)	25.9 (60)	32.5 (66)	0.13
Truncal fat (mm) ^g	25.7, 10.5	36.4, 21.6	< 0.001
Insulin Resistance			
Fasting glucose (mg dl ⁻¹) ^h	89.2, 6.7	92.6, 6.7	< 0.001
Fasting glucose ≥ 100 mg dl ⁻¹ (%), (n) ⁱ	1.7 (4)	12.3 (25)	< 0.001
Fasting Insulin (IU ml ⁻¹) ^h	5.5, 1.6	7.5, 2.6	< 0.001
Fasting insulin (≥ 10 µg dl ⁻¹) (%), (n) ⁱ	2.6 (6)	14.8 (30)	< 0.001
HOMA-IR ^h	1.2, 0.4	1.7, 0.7	< 0.001
HOMA-IR (≥ 3.2) (%), (n) ^j	1.7 (4)	6.9 (14)	< 0.001
QUICKI index	0.16, 0.05	0.15, 0.08	< 0.001

Abbreviations: 3C, three-component; BIA, bioelectrical impedance measurements; BMI, body mass index; GOCS, Growth and Obesity Chilean Cohort Study; HOMA-IR, homeostasis model assessment of IR; IR, insulin resistance; NHANES, National Health study in EEUU; QUICKI, quantitative insulin sensitivity check index; VD, vitamin D; WC, waist circumference. ^aDifferences between the sexes were estimated using t-test, X²-tests, or fisher tests, P < 0.05. ^bBased on Word Health Organization Growth References 2007. ^cSkinfolds equation of body fat from GOCS, Body fat (%) = (1.825*BAZ) + (0.7825*Triceps Skinfold) + (0.3072*Biceps Skinfold) + 15.558. ^dBioimpedance (BIA) using Tanita BC-418 MA. ^eThree-components model, subsample n = 283, girls n = 100, boys n = 183. ^fWC, NHANES III Mexican-Children: cut-off ≥75th percentile (girls at 6 years: 60.4 cm; and boys at 8 years: 66.2 cm). ^gTruncal fatness = calculated by summing abdominal, suprailliac and subscapular skinfold thicknesses.⁴³ ^hVariables not normally distributed were log transformed. ⁱHyperglycemia was defined as ≥ 100 mg dl⁻¹.⁴⁴ ^jHOMA. QUICKI.⁴⁵

Table 2. Association between 25-Hydroxyvitamin D concentrations, adiposity (total and central) and insulin resistance in 435 prepubertal Chilean children by sex

	Girls (n = 232) β (95% CI)	Boys (n = 203) β (95% CI)
Total Adiposity^a		
z Score BMI by age ^b	-0.37 (-0.49, -0.25)*	-0.19 (0.30, -0.08)*
z Body fat % skinfolds ^c	-0.18 (-0.31, -0.05)*	0.02 (-0.05, 0.08)
z Body fat % BIA ^d	-0.34 (-0.46, -0.21)*	-0.31 (-0.44, -0.18)*
z Body fat % 3C model ^e	-0.36 (-0.49, -0.23)*	-0.16 (-0.31, -0.01)*
Central Adiposity^a		
z WC (cm) ^f	-0.34 (-0.46, -0.22)*	-0.27 (-0.41, -0.14)**
z WC/height (cm) ^f	-0.33 (-0.44, -0.21)*	-0.20 (-0.33, -0.08)**
z Truncal fatness (mm) ^g	-0.34 (-0.46, -0.22)*	-0.30 (-0.44, -0.16)*
Insulin resistance^h		
z Fasting insulin (µg dl ⁻¹) ⁱ	-0.35 (-0.48, -0.22)*	-0.33 (-0.45, -0.21)*
z HOMA-IR ^h	-0.30 (-0.43, -0.16)*	-0.29 (-0.42, -0.17)*
z QUICKI index ^j	0.37 (0.19, 0.55)*	0.29 (0.17, 0.42)*

Abbreviations: 3C, three-component; BIA, bioelectrical impedance measurements; BMI, body mass index; CI, confidence interval; GOCS, Growth and Obesity Chilean Cohort Study; HOMA-IR, homeostasis model assessment of IR; IR, insulin resistance; NHANES, National Health study in EEUU; QUICKI, quantitative insulin sensitivity check index; VD, vitamin D; WC, waist circumference. z Standardized coefficient (X-mean/s.d. of the sample). ^aModel 1: Multiple regression analysis adjusted by sex, age and seasons *P < 0.001, **P < 0.05. ^bz Score BMI by age (BAZ) based on Word Health Organization Growth Standards 2007. ^cSkinfolds equation for body fat % from GOCS. ^dBioimpedance (BIA) using Tanita BC-418 MA. ^e3C, subsample n = 283, girls n = 100, boys n = 183. ^fWC. ^gTruncal fatness = calculated by summing abdominal, suprailliac and subscapular skinfold thicknesses.⁴³ ^hModel 2: multiple regression analysis adjusted by sex, age, seasons and BMI by age *P < 0.001, **P < 0.05. ⁱVariables not normally distributed were log transformed. ^jHOMA-IR; QUICKI.⁴⁵

was inversely associated with all indicators of total and central adiposity, but the effect size was lower when using indicators based on skinfolds measurements (-0.18 and 0.02 in girls and boys, respectively). 25(OH)D was also inversely associated with IR indicators and positively associated with the quantitative insulin sensitivity check index insulin sensitivity index in both sexes, even after adjusting by BMI. Overall, effect sizes were weak to moderate (~0.3 for adiposity and IR indicators).

Cut-offs for optimal VD based on adiposity and IR outcomes

As is shown in Table 3, the cut-offs of serum 25(OH)D that best predicted (maximum specificity and sensitivity) higher adiposity and IR was ~30 ng ml⁻¹ in both sexes, considering different indicators of adiposity and IR (see also Supplementary Figures S1 and S2).

Associations between suboptimal VD and high adiposity and IR Table 4 presents the results for logistic models assessing associations between suboptimal VD (defined based on the study cut-off: < 30 ng ml⁻¹), high adiposity and IR. Boys with suboptimal VD had almost twice the risk of having high adiposity (that is, odds ratio (OR) = 2.0 (1.0, 3.9) for obesity and 2.2 (1.2, 4.0) for central obesity), while girls had almost three times greater risk (that is, OR = 4.8 (1.9, 12.1) for obesity and 2.4 (1.4, 4.3) for central obesity). Boys and Girls with suboptimal VD have almost three

virtually non-existent among girls (< 3% for both indexes) while more prevalent among boys (~15% and ~7%, respectively; P for sex differences < 0.05).

Serum 25-Hydroxyvitamin D associations with adiposity and insulin resistance

Standardized coefficients for the associations of 25(OH)D and adiposity and IR indicators are presented in Table 2. Serum 25(OH)D

Table 3. Cut-offs of 25-Hydroxyvitamin D associated with indicators of adiposity and insulin resistance in prepubertal Chilean Children

Indicators	AUC (95%)	Sensitivity	Specificity	Youden index ^a	Cut-off 25(OH)D ^a
Girls n = 232					
BAZ (≥ 2 s.d.) ^b	0.75, (0.66–0.84)	61.0	82.6	0.434	31.3
BF % (BIA) ≥ 75 th percentile ^c	0.69, (0.62–0.77)	68.4	63.8	0.322	30.9
WC ≥ 75 th percentile ^d	0.65, (0.58–0.72)	60.0	62.0	0.218	31.9
Truncal fatness ≥ 75 th percentile ^e	0.64, (0.57–0.72)	60.3	64.8	0.251	31.9
Fasting Insulin ≥ 75 th percentile ^f	0.71, (0.59–0.83)	83.4	55.6	0.390	28.0
HOMA-IR ≥ 75 th percentile ^g	0.72, (0.60–0.83)	83.0	53.8	0.368	28.0
QUICKI ≤ 25 th percentile ^g	0.76, (0.65–0.87)	83.3	60.9	0.442	28.0
Boys n = 203					
BAZ (≥ 2 s.d.) ^b	0.66, (0.58–0.75)	62.3	59.2	0.275	28.9
BF % (BIA) ≥ 75 th percentile ^c	0.71, (0.64–0.78)	62.0	73.1	0.349	30.5
WC ≥ 75 th percentile ^d	0.66, (0.58–0.74)	63.5	63.6	0.271	29.7
Truncal fatness ≥ 75 th percentile ^e	0.65, (0.57–0.72)	60.4	68.6	0.290	30.4
Fasting Insulin ≥ 75 th percentile ^f	0.74, (0.66–0.82)	73.0	69.1	0.421	27.5
HOMA-IR ≥ 75 th percentile ^g	0.74, (0.67–0.82)	73.2	70.4	0.436	27.5
QUICKI ≤ 25 th percentile ^g	0.72, (0.64–0.80)	71.9	70.0	0.419	27.5

Abbreviations: AUC, area under curve; BF, body fat; BIA, bioelectrical impedance measurements; BMI, body mass index; HOMA-IR, homeostasis model assessment of IR; NHANES, National Health study in EEUU; QUICKI, quantitative insulin sensitivity check index; WC, waist circumference. ^aYouden index (sensitivity-(1-specificity)), and the point with shortest distance from the point (0, 1) $((1 - \text{sensitivity})^2 + (1 - \text{specificity})^2)^{0.5}$. ^bz Score BMI by age (BAZ) based on World Health Organization Growth Standards 2007. ^cBioimpedance (BIA) using Tanita BC-418 MA. Cut-off ≥ 75 percentile: girls 25.8% BF and boys 28.9% BF. ^dWC, NHANES III percentiles Mexican-Children: cut-off ≥ 75 th percentile girls at 6 years: 60.4 cm; boys at 8 years: 66.2 cm⁴² WC/height, cut-off > 0.5 . ^eTruncal fatness = calculated by summing abdominal, suprailiac and subscapular skinfold thicknesses ≥ 75 percentile.⁴³ ^fFasting insulin ≥ 75 percentile: girls 5.6 $\mu\text{g dl}^{-1}$, boys 9.3 $\mu\text{g dl}^{-1}$. ^gHOMA-IR ≥ 75 percentile: girls: 1.25, boys: 2.2. QUICKI ≤ 25 percentile: girls 0.35, boys: 0.37.

Table 4. OR of the association between suboptimal vitamin D ($< 30 \text{ ng ml}^{-1}$) and indicators of total and central adiposity and insulin resistance in 435 prepubertal Chilean children by sex

	Girls (n = 232) OR (95% CI)	Boys (n = 203) OR (95% CI)
Total adiposity^a		
Obesity BAZ (≥ 2 s.d.) ^b	4.8 (1.9, 12.1)*	2.0 (1.0, 3.9)**
BF % BIA ≥ 75 th percentile ^c	3.6 (1.9, 6.6)**	3.0 (1.7, 5.4)*
BF % 3C model ≥ 75 th percentile ^d	8.1 (2.7, 24.1)*	2.8 (1.1, 7.1)**
Central adiposity^a		
WC ≥ 75 th percentile ^e	2.4 (1.4, 4.3)*	2.2 (1.2, 4.0)**
WC/height $> 0.5 \text{ cm}^e$	3.1 (1.7, 5.9)*	2.0 (1.2, 3.5)**
Truncal fatness ≥ 75 th percentile ^f	2.8 (1.5, 5.1)*	1.8 (1.0, 3.3)
Insulin resistance^g		
Fasting insulin ≥ 75 percentile ^h	3.3 (1.4, 8.2)*	3.4 (1.6, 7.0)*
HOMA-IR ≥ 75 percentile ⁱ	2.9 (1.2, 7.1)**	3.3 (1.6, 7.0)*
QUICKI ≤ 25 percentile ⁱ	3.7 (1.4, 9.7)*	3.1 (1.5, 6.7)*

^aModel 1: logistic regression analysis adjusted by, age and seasons $*P < 0.001$, $**P < 0.05$. ^bz-score BMI by Age (BAZ) based on World Health Organization Growth Standards 2007. ^cBioimpedance (BIA) using Tanita BC-418 MA. Cut-off ≥ 75 percentile: girls 25.8% BF and boys 28.9% BF. ^d3C model, subsample $n = 283$, girls $n = 100$, boys $n = 183$. ≥ 75 th percentile: girls 36.1 BF% and boys 33.8 BF%. ^eWC, NHANES III percentiles Mexican-Children: cut-off ≥ 75 th percentile in girls at 6 years: 60.4 cm; and boys at 8 years: 66.2 cm⁴² WC/Height, cut-off > 0.5 . ^fTruncal fatness = calculated by summing abdominal, suprailiac and subscapular skinfold thicknesses.³⁷ ^gModel 2: logistic regression analysis adjusted by age, seasons, BMI by age $*P < 0.001$, $**P < 0.05$. ^hFasting insulin ≥ 75 percentile: girls 5.6 $\mu\text{g dl}^{-1}$, Boys 9.3 $\mu\text{g dl}^{-1}$. ⁱHOMA-IR ≥ 75 percentile: girls: 1.25, boys: 2.2. QUICKI ≤ 25 percentile: girls: 0.35, boys: 0.37.⁴⁵

times more IR risk than children with optimal VD concentrations even after adjusting for BMI (that is, OR = 3.3 (1.4, 8.2); OR = 3.4 (1.6, 7.0) for hyperinsulinism and 2.9 (1.2, 7.1), OR = 3.3 (1.6, 7.0) for IR in girls and boys, respectively).

DISCUSSION

Serum 25(OH)D was inversely related to total and central adiposity using both simple techniques (i.e. BAZ, BIA, WC, WC/H and truncal fatness) or the gold standard method (3C model) in prepubertal Chilean children. Moreover, 25(OH)D was also inversely associated with IR, even after adjusting by total adiposity. For the study sample, a serum 25(OH)D of $< 30 \text{ ng ml}^{-1}$ was the best predictor of total and central adiposity and of IR. Children with suboptimal VD had two to three times greater risk of obesity, high BF% and central adiposity; and 3–4 times greater risk for IR.

Serum 25-hydroxyvitamin D associations with body fat

We found that associations between 25(OH)D and simple adiposity indicators varied from -0.16 to -0.37 , (all P -value < 0.05); these results were further confirmed using a robust method such as 3C model based on plethysmography and deuterium measurements (OR: -0.21 (-0.32 , -0.09)). These results are in agreement with the hypothesis of the migration of VD to adipose tissue (AT),^{9,50} and/or with the emerging hypothesis of AT as a target for the active form of VD (1,25-hydroxyvitamin D).^{2,6} This indicates a need to further study the role of VD given the current obesity epidemic experienced by children worldwide.

Serum 25-hydroxyvitamin D associations with insulin resistance

In concordance with previous evidence,^{14–17,25–27} we observed an inverse relation between 25(OH)D concentration, fasting insulin and HOMA-IR; and, a direct relationship between 25(OH)D concentrations and insulin sensitivity (quantitative insulin sensitivity check index), after adjusting for adiposity. We believe these results are of special interest during the prepubertal period because suboptimal VD can be considered as an additional stressor to the physiologic IR that accompanies pubertal progression.⁵¹

Cut-offs of serum 25-hydroxyvitamin D that best reflect adiposity (total and central) and insulin resistance in prepubertal children. There is an ongoing debate on the cutoff values that best define optimal VD when considering the metabolic effects of VD.³⁵

We found that serum 25(OH)D is closely associated with (total and central) adiposity; AUC ranges from 0.64 to 0.75 depending on the indicator and IR with an AUC ranging from 0.71 to 0.76. The relationships between these estimates are stronger than what has been previously reported. A study in Irani adolescents reported 11.6 ng ml⁻¹ of serum 25(OH)D value as a cut-off based on IR with an AUC of 0.59 (95% CI: 0.52–0.66 for HOMA-IR > 2.1).⁵² A study in Korean adolescents showed for abdominal obesity (WC ≥ 90th percentile for age and sex) an AUC of 0.58 (95% CI: 0.51–0.65) with a cutoff of 17.6 ng ml⁻¹ of serum 25(OH)D.⁵³

Differences between results from different studies might be explained partially by the effect of puberty on body composition and IR, which could affect the relation between VD and IR in adolescents groups.^{23,30–32} The optimal cut-off of serum 25(OH)D ~ 30 ng ml⁻¹ suggests that our study is concordant with the cut-off suggested by the US Endocrine Society Task Force based on bone health observations:⁵⁴ (a) in postmenopausal women intestinal absorption of calcium is maximized above 32 ng ml⁻¹ of 25-OHD,⁵⁵ and (b) when 25(OH)D concentration reaches a nadir between 30–40 ng ml⁻¹ the concentration of parathyroid hormone decreases.⁵⁶ Interestingly, a cut-off of 30 ng ml is also in line with results from a meta-analysis that shows that pregnant women with serum 25(OH)D < 30 ng ml⁻¹ present higher risk of gestational diabetes (pooled odds 1.49, 95% CI: 1.18–1.89), pre-eclampsia (pooled odds 1.79, 95% CI: 1.25–2.58) and small for gestational age infants (pooled odds 1.85, 95% CI: 1.52–2.26).⁵⁷ Additionally, a recent meta-analysis showed that serum 25(OH)D concentrations < 30 ng ml⁻¹ were associated with higher 'all cause' mortality even after adjusting for age (*P* < 0.01).⁵⁸ Thus, the well accepted cut-off of 30 ng ml⁻¹ of 25(OH)D for bone related outcomes may also be applicable to extraskelatal outcomes.

Associations between suboptimal VD and high adiposity and IR we observed that children with suboptimal 25(OH)D concentrations (< 30 ng ml⁻¹) had two and three times greater risk for obesity, high BF% and central adiposity; and 3–4 times greater risk of IR. Effects tended to be higher in girls than in boys. We are not certain what may account for the sex differences however dimorphism of body composition during onset of puberty may account in part for this. In boys, testosterone concentrations increases fat free mass while in girls, estrogens concentrations induce fat redistribution towards the extremities.⁵⁹ Further research in other life stages is needed to clarify this issue.

Our study is not exempt from limitations. Its cross-sectional design does not allow us to claim causality/directionality; however further follow-up of this cohort may provide some insight on the directions of these associations. At this early age there is also a lack of consensus about the adequate cut-points to define limits for normal adiposity and IR. We used several available cut-offs from the WHO multicenter study,⁴⁰ from the National Health study in EEUU (NHANES III) and from the American Academy of Pediatrics that involved Hispanic population;^{42,44,45} and if not available, we used as a cut-off-point the ≥ 75th percentile of the sample.

This study also has several strengths. We use a number of indicators of total and central adiposity, even including a gold standard method allowing us to assess the consistency of our finding; this was also true for the case of IR indicators. In addition, to our best knowledge, this is the first study that examines extensively the serum 25(OH)D thresholds as a marker of VD status based on different total and central adiposity and IR indicators in a large sample of children; moreover, the longitudinal nature of our study will allow us to confirm the validity of these findings for other long-term outcomes.

CONCLUSION

Serum 25(OH)D was inversely associated with adiposity (total and central) and IR indicators in prepubertal Chilean children. The traditional cutoff of VD sufficiency (≥ 30 ng ml⁻¹) may also be adequate to assess obesity and IR related metabolic risks associated to VD in this age group. These findings highlight the importance of preventing obesity and suboptimal VD from early ages to avoid complications associated with IR and skeletal maturation during puberty.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

GC did this work as part of his doctoral thesis in Human Nutrition at the University of Chile, he wrote the first draft; CC and RU contributed in interpreting the data; all authors were involved in analyzing results and reviewing the paper. We thank the study personnel and GOCs participants that continue to collaborate with our research. Supported by FONDECYT grant no 1120326 (CC), grant no 1110085 (DLdR). GC is beneficiary of a PhD scholarship from Government of Chile (Conicyt, Development of Human Capital Program).

REFERENCES

- Prentice A, Schoenmakers I, Laskey MA, de Bono S, Ginty F, Goldberg GR. Nutrition and bone growth and development. *Proc Nutr Soc* 2006; **65**: 348–360.
- Wamberg L, Christiansen T, Paulsen SK, Fisker S, Rask P, Rejnmark L *et al*. Expression of vitamin D-metabolizing enzymes in human adipose tissue—the effect of obesity and diet-induced weight loss. *Int J Obes (Lond)* 2013; **37**: 651–657.
- Bischoff HA, Borchers M, Gudat F, Duermueller U, Theiler R, Stahelin HB *et al*. In situ detection of 1,25-dihydroxyvitamin D₃ receptor in human skeletal muscle tissue. *Histochem J* 2001; **33**: 19–24.
- Johnson JA, Grande JP, Roche PC, Kumar R. Immunohistochemical localization of the 1,25(OH)₂D₃ receptor and calbindin D28k in human and rat pancreas. *Am J Physiol* 1994; **267**: E356–E360.
- Christakos S, Hewison M, Gardner DG, Wagner CL, Sergeev IN, Rutten E *et al*. Vitamin D: beyond bone. *Ann N Y Acad Sci* 2013; **1287**: 45–58.
- Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. *Br J Nutr* 2012; **108**: 1915–1923.
- Khaw K-T, Luben R, Wareham N. Serum 25-hydroxyvitamin D, mortality, and incident cardiovascular disease, respiratory disease, cancers, and fractures: a 13-y prospective population study. *Am J Clin Nutr* 2014; **100**: 1361–1370.
- Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE *et al*. Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. *Diabetes Care* 2013; **36**: 1422–1428.
- Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. *Am J Clin Nutr* 2000; **72**: 690–693.
- George PS, Pearson ER, Witham MD. Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis. *Diabet Med* 2012; **29**: e142–e150.
- Lenders CM, Feldman HA, Von Scheven E, Merewood A, Sweeney C, Wilson DM *et al*. Relation of body fat indexes to vitamin D status and deficiency among obese adolescents. *Am J Clin Nutr* 2009; **90**: 459–467.
- Elizondo-Montemayor L, Ugalde-Casas PA, Serrano-González M, Cuello-García CA, Borbolla-Escoboza JR. Serum 25-hydroxyvitamin d concentration, life factors and obesity in Mexican children. *Obesity (Silver Spring)* 2010; **18**: 1805–1811.
- Gilbert-Diamond D, Baylin A, Mora-Plazas M, Marin C, Arsenault JE, Hughes MD *et al*. Vitamin D deficiency and anthropometric indicators of adiposity in school-age children: a prospective study. *Am J Clin Nutr* 2010; **92**: 1446–1451.
- Alemzadeh R, Kichler J, Babar G, Calhoun M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. *Metabolism* 2008; **57**: 183–191.
- Reis JP, von Mühlen D, Miller ER, Michos ED, Appel LJ. Vitamin D status and cardiometabolic risk factors in the United States adolescent population. *Pediatrics* 2009; **124**: e371–e379.
- Reyman M, Verrijn Stuart AA, van Summeren M, Rakhshandehroo M, Nuboer R, de Boer FK *et al*. Vitamin D deficiency in childhood obesity is associated with high levels of circulating inflammatory mediators, and low insulin sensitivity. *Int J Obes (Lond)* 2013; **38**: 46–52.

- 17 Oliveira RMS, Novaes JF, Azeredo LM, Azeredo LM, Cândido APC, Leite ICG. Association of vitamin D insufficiency with adiposity and metabolic disorders in Brazilian adolescents. *Public Health Nutr* 2014; **17**: 787–794.
- 18 Kelly A, Brooks LJ, Dougherty S, Carlow DC, Zemel BS. A cross-sectional study of vitamin D and insulin resistance in children. *Arch Dis Child* 2011; **96**: 447–452.
- 19 Garanty-Bogacka B, Syrenicz M, Goral J, Krupa B, Syrenicz J, Walczak M et al. Serum 25-hydroxyvitamin D (25-OH-D) in obese adolescents. *Endokrynol Pol* 2011; **62**: 506–511.
- 20 Kolokotroni O, Papadopoulou A, Yiallourou PK, Raftopoulos V, Kouta C, Lamniso D et al. Association of vitamin D with adiposity measures and other determinants in a cross-sectional study of Cypriot adolescents. *Public Health Nutr* 2014; **18**: 112–121.
- 21 Creo AL, Rosen JS, Ariza AJ, Hidaka KM, Binns HJ. Vitamin D levels, insulin resistance, and cardiovascular risks in very young obese children. *J Pediatr Endocrinol Metab* 2013; **26**: 97–104.
- 22 Poomthavorn P, Saowan S, Mahachoklertwattana P, Chailurkit L, Khlairit P. Vitamin D status and glucose homeostasis in obese children and adolescents living in the tropics. *Int J Obes (Lond)* 2012; **36**: 491–495.
- 23 Aypak C, Türedi O, Yüce A. The association of vitamin D status with cardiometabolic risk factors, obesity and puberty in children. *Eur J Pediatr* 2014; **173**: 367–373.
- 24 Wells JC, Fuller NJ, Dewit O, Fewtrell MS, Elia M, Cole TJ. Four-component model of body composition in children: density and hydration of fat-free mass and comparison with simpler models. *Am J Clin Nutr* 1999; **69**: 904–912.
- 25 Delvin EE, Lambert M, Levy E, O'Loughlin J, Mark S, Gray-Donald K et al. Vitamin D status is modestly associated with glycemia and indicators of lipid metabolism in French-Canadian children and adolescents. *J Nutr* 2010; **140**: 987–991.
- 26 Roth CL, Elfers C, Kratz M, Hoofnagle AN. Vitamin d deficiency in obese children and its relationship to insulin resistance and adipokines. *J Obes* 2011; **2011**: 495101.
- 27 Jang HB, Lee H-J, Park JY, Kang J-H, Song J. Association between serum vitamin d and metabolic risk factors in Korean schoolgirls. *Osong Public Health Res Perspect* 2013; **4**: 179–186.
- 28 Torun E, Gönüllü E, Ozgen IT, Cindemir E, Oktem F. Vitamin d deficiency and insufficiency in obese children and adolescents and its relationship with insulin resistance. *Int J Endocrinol* 2013; **2013**: 631845.
- 29 Gutiérrez-Medina S, Gavela-Pérez T, Domínguez-Garrido MN, Blanco-Rodríguez M, Garcés C, Rovira A et al. High prevalence of vitamin D deficiency among Spanish obese children and adolescents. *An Pediatr (Barc)* 2014; **80**: 229–235.
- 30 Gutiérrez Medina S, Gavela-Pérez T, Domínguez-Garrido MN, Gutiérrez-Moreno E, Rovira A, Garcés C et al. The influence of puberty on vitamin D status in obese children and the possible relation between vitamin D deficiency and insulin resistance. *J Pediatr Endocrinol Metab* 2015; **28**: 105–110.
- 31 Khadgawat R, Thomas T, Gahlot M, Tandon N, Tangpricha V, Khandelwal D et al. The effect of puberty on interaction between vitamin D status and insulin resistance in obese Asian-Indian Children. *Int J Endocrinol* 2012; **2012**: 173581.
- 32 Buyukinan M, Ozen S, Kokkun S, Saz EU. The relation of vitamin D deficiency with puberty and insulin resistance in obese children and adolescents. *J Pediatr Endocrinol Metab* 2012; **25**: 83–87.
- 33 Zerwekh JE. Blood biomarkers of vitamin D status. *Am J Clin Nutr* 2008; **87**: 1087S–1091S.
- 34 Pearce SHS, Cheetham TD. Diagnosis and management of vitamin D deficiency. *BMJ* 2010; **340**: b5664.
- 35 Bouillon R, Van Schoor NM, Gielen E, Boonen S, Mathieu C, Vanderschueren D et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. *J Clin Endocrinol Metab* 2013; **98**: E1283–E1304.
- 36 Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arviso RA et al. IOM committee members respond to Endocrine Society vitamin D guideline. *J Clin Endocrinol Metab* 2012; **97**: 1146–1152.
- 37 Kain J, Corvalán C, Lera L, Galván M, Uauy R. Accelerated growth in early life and obesity in preschool Chilean children. *Obesity (Silver Spring)* 2009; **17**: 1603–1608.
- 38 Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. *Behav Res Methods* 2009; **41**: 1149–1160.
- 39 WHO Multicentre Growth Reference Study Group. Reliability of anthropometric measurements in the WHO Multicentre Growth Reference Study. *Acta Paediatr Suppl* 2006; **450**: 38–46.
- 40 Child Growth WHO. Standards based on length/height, weight and age. *Acta Paediatr Suppl* 2006; **450**: 76–85.
- 41 Fuller NJ, Jebb SA, Laskey MA, Coward WA, Elia M. Four-component model for the assessment of body composition in humans: comparison with alternative methods, and evaluation of the density and hydration of fat-free mass. *Clin Sci (Lond)* 1992; **82**: 687–693.
- 42 Fernández JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. *J Pediatr* 2004; **145**: 439–444.
- 43 Corvalán C, Uauy R, Kain J, Martorell R. Obesity indicators and cardiometabolic status in 4-y-old children. *Am J Clin Nutr* 2010; **91**: 166–174.
- 44 Salvatore D, Satnick A, Abell R, Messina CR, Chawla A. The prevalence of abnormal metabolic parameters in obese and overweight children. *JPEN J Parenter Enteral Nutr* 2014; **38**: 852–855.
- 45 Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. *Pediatrics* 2005; **115**: e500–e503.
- 46 Dirección Meteorológica de Chile. Available at: <http://www.meteochile.gob.cl>.
- 47 Tanner JM. The measurement of maturity. *Trans Eur Orthod Soc* 1975: 45–60.
- 48 Pereira A, Garmendia ML, González D, Kain J, Mericq V, Uauy R et al. Breast bud detection: a validation study in the Chilean Growth Obesity Cohort Study. *BMC Womens Health* 2014; **14**: 96.
- 49 Fawcett T. An introduction to ROC analysis. *Pattern Recognit Lett* 2006; **27**: 861–874.
- 50 Drincic AT, Armas LAG, Van Diest EE, Heaney RP. Volumetric dilution, rather than sequestration best explains the low vitamin D status of obesity. *Obesity (Silver Spring)* 2012; **20**: 1444–1448.
- 51 Hannon TS, Janosky J, Arslanian SA. Longitudinal study of physiologic insulin resistance and metabolic changes of puberty. *Pediatr Res* 2006; **60**: 759–763.
- 52 Sharifi F, Mousavinasab N, Mellati AA. Defining a cutoff point for vitamin D deficiency based on insulin resistance in children. *Diabetes Metab Syndr* 2013; **7**: 210–213.
- 53 Nam GE, Kim DH, Cho KH, Park YG, Han K, Do, Choi YS et al. Estimate of a predictive cut-off value for serum 25-hydroxyvitamin D reflecting abdominal obesity in Korean adolescents. *Nutr Res* 2012; **32**: 395–402.
- 54 Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 2011; **96**: 1911–1930.
- 55 Heaney RP, Dowell MS, Hale CA, Bendich A. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. *J Am Coll Nutr* 2003; **22**: 142–146.
- 56 Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT et al. Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. *J Clin Endocrinol Metab* 2005; **90**: 3215–3224.
- 57 Aghajafari F, Nagulesapillai T, Ronskley PE, Tough SC, O'Beirne M, Rabi DM. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. *BMJ* 2013; **346**: f1169.
- 58 Garland CF, Kim JJ, Mohr SB, Gorham ED, Grant WB, Giovannucci EL et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. *Am J Public Health* 2014; **104**: e43–e50.
- 59 Wells JC. Sexual dimorphism of body composition. *Best Pract Res Clin Endocrinol Metab* 2007; **21**: 415–430.

Supplementary Information accompanies this paper on International Journal of Obesity website (<http://www.nature.com/ijo>)